Is Greece the landing beach for compulsory licensing in Europe?
This article was originally published in Scrip
Executive Summary
Activists calling for compulsory licenses to allow domestic manufacturers to undercut imported drug sales are nothing new: Brazil and India have them, and now they have compulsory licensing, too. As do other emerging market nations. But the latest call for governmental IP-snatching comes from Greece. This is a country that has a curious historical disdain for patents, precious little domestic pharma industry, drug shortages caused by price cutting and an immediate need to cull its drug bill. If a compulsory licensing advance party was going to land anywhere in the EU, Greece is a beachhead that is less hostile than most.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.